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Elevated  cellular  levels  of  protein  O-linked  β-N-acetyl-
glucosamine  (O-GlcNAc)  through  hexosamine  biosynthesis 
pathway  (HBP)  are  suggested  to  contribute  to  cardiovascular 
adverse effects under chronic hyperglycemic condition associated 
with oxidative stress and inflammation. Conversely, enhancing 
O-GlcNAc levels have also been demonstrated being protective 
against  myocardial  ischemia/reperfusion  injury.  We  recently 
demonstrated that hyperglycemia increases oxidative stress and 
HBP flux in endothelial cells and enhances endothelial expres-
sion of vascular adhesion molecule-1 (VCAM-1) and intercellular 
adhesion molecule-1 (ICAM-1) in response to tumor necrosis 
factor-α  (TNFα)  through  oxidative  stress  rather  than  HBP 
pathway. Here we present further complementary data showing 
that enhancing O-GlcNAc levels by glucosamine does not mimic 
hyperglycemia’s effect on  TNFα-induced endothelial VCAM-1 
and ICAM-1 expression. Glucosamine however inhibits ICAM-1 
(not VCAM-1) expression and induces superoxide generation in 
the cells. The results further suggest that increased O-GlcNAc 
levels do not mediate the enhancing effect of hyperglycemia on 
the endothelial inflammatory responses to TNFα. In contrast, 
it exerts certain anti-inflammatory effects accompanied by pro-
oxidative properties. Further work should delineate the exact role 
of HPB pathway in different aspects of cardiovascular functions, 
especially those of diabetic cardiovascular complications.
Introduction
The  posttranslational  modification  of  serine  and  threo-
nine  residues  of  proteins  by  the  O-linked  attachment  of 
the  monosaccharide  β-N-acetylglucosamine  (O-GlcNAc),  i.e., 
protein O-GlcNAcylation is emerging to play critical roles in   
regulation  of  wide  spectrum  of  cellular  functions  including 
gene  transcription,  protein  translation,  proteasomal  degrada-
tion  and  signal  transduction.1  An  elevated  cellular  level  of 
O-GlcNAc is best described under chronic hyperglycemic condi-
tion in which an increased portion of glucose entering the cell is 
shunted from glycolysis to the hexosamine biosynthesis pathway   
(HBP).1In  the  HBP  pathway,  glucose  is  converted  to 
glucosamine-6-phosphate  by  the  rate-limiting  enzyme, 
L-glutamine:D-fructose-6-phosphate amidotransferase (GFAT). 
Glucosamine-6-phosphate  is  further  metabolized  to  UDP-N-
acetylglucosamine (UDP-GlcNAc) that serves as the major substrate 
for the formation of O-GlcNAc-modified proteins at serine and 
threonine residues catalysed by the UDP-GlcNAc:polypeptide 
O-β-N-acetyl-glucosaminyltransferase  (OGT).1  It  has  been 
suggested that elevated O-GlcNAc contributes to many delete-
rious  effects  of  hyperglycemia,  i.e.,  glucotoxicity  including 
insulin resistance, diabetic cardiovascular damage associated with 
oxidative stress and inflammation.1-3
Conversely, there is a growing body of data demonstrating that 
enhancing  O-GlcNAc  level  is  protective  against  cellular  injury, 
improves cell survival and reduces ischemia/reperfusion injury and 
myocardial infarction in animal models.4,5 The cellular O-GlcNAc 
levels are augmented under the acute non-diabetic stress condi-
tion i.e., ischemic preconditioning in the heart.6,7 An increase in 
O-GlcNAc level can be induced pharmacologically with the addi-
tion of exogenous glucosamine, which enters cells via the glucose 
transporter  system  and  is  phosphorylated  to  glucosamine-6- 
phosphate by hexokinase, thus bypassing GFAT and leading to 
a rapid increase in UDP-GlcNAc levels.8 Glucosamine has been 
shown to possess anti-inflammatory properties in variety of disease 
models including rheumatoid arthritis, cardiac allograft survival, 
balloon angioplasty induced arterial injury and cardiac ischemia/
reperfusion injury.9-11 The mechanisms of the apparent paradox 
of  the  cellular  protective  and  deleterious  effects  of  increased 
O-GlcNAc levels are not known. It is also not clear what is the 
functional role of the increased O-GlcNAc under the hypergly-
cemic condition in cardiovascular system.
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In  our  most  recently  published  article,12  we  showed  that 
in  cultured  human  umbilical  vein  endothelial  cells  (HUVEC) 
hyperglycemia increases oxidative stress and HBP flux, amplifies 
endothelial inflammatory responses i.e., VCAM-1 and ICAM-1 
expression in response to TNFα, and impairs endothelium-depen-
dent relaxations in isolated blood vessels mainly through oxidative 
stress rather than through HBP pathway. In the current article we 
present further complementary results showing functional roles of 
increased O-GlcNAc levels in regulation of endothelial inflamma-
tory responses and oxidative stress.
Results
Our  recent  study12  showed  that  hyperglycemia  enhances 
endothelial expression of VCAM-1 and ICAM-1 in response to 
TNFα  through  increased  oxidative  stress  rather  than  through 
increased cellular O-GlcNAc levels. In the current study, we further 
investigated  whether  treatment  of  the  cells  with  glucosamine 
to  enhance  O-GlcNAc  levels  could  mimic  the  hyperglycemia’s 
effect. In contrast to hyperglycemia,12 incubation of the cells with 
glucosamine (0.1 and 0.5 mmol/L) for five days did not enhance 
TNFα  (1  ng/ml,  24  hours)  induced  VCAM-1  and  ICAM-1 
protein  levels,  but  inhibited  ICAM-1  (not  VCAM-1)  expres-
sion  (Fig.  1).  The  results  further  support  our  conclusion  that 
increased O-GlcNAc does not contribute to the hyperglycemia-
induced upregulation of endothelial expression of the adhesion 
molecules in response to TNFα. Of note, glucosamine itself had 
no significant effects on the basal level of endothelial expression 
of the adhesion molecules (Fig. 1). In that recent study, we also 
showed  that  hyperglycemia  further  enhances  oxidative  stress  in 
response to TNFα,12 this interaction between high glucose and 
TNFα was however not observed between glucosamine and TNFα   
(Fig. 2). Although incubation of the cells with glucosamine alone 
(0.5 mol/L, 5 days) stimulated superoxide generation (similar to 
the  high  glucose  condition12),  it  however  did  not  significantly 
affect TNFα  (1  ng/ml,  10  minutes)-induced  superoxide  anion 
production  as  demonstrated  by  the  dihydroethidium  (DHE) 
fluorescence staining in the endothelial cells (Fig. 2), suggesting 
pro-oxidative properties of the HBP flux in endothelial cells.
Discussion
Protein O-GlcNAc modification has been recently shown to 
play important roles in regulation of variety of cellular functions.1 
Under chronic hyperglycemic conditions of in vitro and in vivo 
model  systems,  increased  HBP  flux  in  different  tissue/cells  has 
been implicated in pathogenesis of insulin resistance and diabetic 
cardiovascular complications.13,14 For example, both high glucose 
and glucosamine increases O-GlcNAc modification of Akt/eNOS, 
leading to decreased activation of Akt/eNOS,15-17 an important 
vascular protective mechanism exerted by the vascular endothe-
lial cells.18 Moreover, it has been demonstrated that elevation of 
O-GlcNAc levels by high glucose, glucosamine and overexpression 
of  GFAT  enhances  plasminogen  activator  inhibitor-1  (PAI-1) 
expression in mesangial cells via activation of Sp1 site.19 Increasing 
O-GlcNAc  by  glucosamine  also  reduces  vascular  sprouting  in 
mouse aortic rings and in aortas from diabetic mouse models.20 
All the studies implicate that increased HBP flux plays a role in the 
pathogenesis of diabetic cardiovascular complications.
The  biological  functions  of  HBP  pathway  in  cardiovascular 
disease are recently challenged by a growing number of studies 
demonstrating that elevation of O-GlcNAc levels protects cardio-
myocytes from ischemia/reperfusion injury and reduces myocardial 
infarction in animal models.4-7,9 The cellular O-GlcNAc levels are 
transiently augmented under the acute non-diabetic stress condi-
tion i.e., ischemic preconditioning in the heart.6,7 Augmentation of 
O-GlcNAc with high glucose or glucosamine improves cell survival, 
whereas decrease in O-GlcNAc levels reduces cell viability.4-7,9
In our most recently published article,12 we investigated the 
roles  of  oxidative  stress  and  HBP  pathway  in  hyperglycemia-
induced  endothelial  inflammatory  responses  and  endothelial 
dysfunction. We provided evidence that hyperglycemia increases 
oxidative stress and HBP flux in endothelial cells and enhances 
Glucosamine, superoxide anion and ICAM-1 expression
Figure  1.  Effects  of  glucosamine  on  endothelial  VCAM-1  and  ICAM-1 
expression. (A) Immunoblotting demonstrates that treatment of HUVECs 
with glucosamine (0.1 or 0.5 mmol/L, 5 days) had no effects on VCAM-1, 
but reduced ICAM-1 protein expression in response to TNFα (1 ng/ml, 
24 hours, n = 3). (B) Quantification of the above results. *p < 0.05 vs. 
TNFα alone.Glucosamine, superoxide anion and ICAM-1 expression
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O-GlcNAc level does not enhance TNFα-induced VCAM-1 and 
ICAM-1  protein  expression.  It  however  inhibits  ICAM-1  (not 
VCAM-1)  expression.  Glucosamine  itself  does  not  have  effects 
on endothelial expression of the adhesion molecules. The results 
thus provide further evidence that increased O-GlcNAc does not 
seem  to  play  a  role  in  hyperglycemia-induced  upregulation  of 
endothelial expression of the adhesion molecules in response to 
TNFα. The results are also in line with numerous experimental 
and  clinical  studies  showing  that  glucosamine  exhibits  anti-
inflammatory effects and is used to treat several diseases associated 
with inflammation.9-11 The inhibition of ICAM-1 expression by 
glucosamine seems not mediated by blockade of oxidative stress, 
since  glucosamine  itself  induces  superoxide  anion  generation 
and  does  not  inhibit TNFα-induced  superoxide  production  as 
demonstrated by the DHE fluorescence staining in the endothelial 
cells. The pro-oxidative properties of glucosamine have also been 
reported in renal mesangial cells and pancreatic β-cells.21,22 The 
results implicate that elevation of O-GlcNAc may contribute to the 
oxidative stress associated with hyperglycemia.
In  conclusion,  the  results  presented  here  provide  further 
evidence that HBP pathway does not mediate the enhancing effect 
of hyperglycemia on the endothelial inflammatory responses to 
TNFα. In contrast, glucosamine may exert certain anti-inflam-
matory  effect  in  the  context  of  endothelial  adhesion  molecule 
expression through enhancing O-GlcNAc level accompanied by 
pro-oxidative properties. The pro-oxidative and anti-inflammatory 
effects  of  glucosamine  might  explain  the  paradoxical  effects  of 
enhancing O-GlcNAc in cardiovascular system reported by afore-
mentioned  various  studies.  Further  work  should  delineate  the 
definite role of HPB pathway in different aspects of cardiovascular 
functions, e.g., (1) cardiac vs. vascular injury; (2) effects of acute 
vs. chronic HBP flux; and (3) effects of diabetic vs. non-diabetic 
activation of HBP pathway.
Materials and Methods
Materials. D-(+)-glucosamine hydrochloride and chemicals for 
immunoblotting were purchased from Sigma (Buchs, Switzerland); 
antibodies against ICAM-1 and VCAM-1 were from Santa Cruz 
Biotechnology (Munningen, Switzerland); IRDye 800-conjugated 
affinity  purified  goat  anti-rabbit  IgG  Fc  was  purchased  from 
BioConcept (Allschwil, Switzerland); Alexa fluor 680-conjugated 
goat  anti-mouse  IgG  (H  +  L)  was  from  Invitrogen;  dihy-
droethidium  (DHE)  was  purchased  from  Invitrogen  (Lucerne, 
Switzerland). Endothelial cell growth supplement pack was from 
PromoCell (Allschwil, Switzerland), and all cell culture media and 
materials were purchased from GIBCO (Lucerne, Switzerland).
Endothelial cell culture. Endothelial cells were isolated from 
human  umbilical  veins  and  characterized  as  described.12  Cells 
from the second to fourth passages were used. The endothelial cells 
were cultured in low-glucose (LG, 5.5 mmol/l) DMEM supple-
mented with 5% fetal calf serum (FCS), endothelial cell growth 
supplement and 0.6 nmol/l insulin. To study effects of O-GlcNAc 
on endothelial expression of adhesion molecules, the cells were 
incubated with 0.1 mmol/L or 0.5 mmol/l of glucosamine for 
four days. The cells were then cultured in the medium containing 
endothelial inflammatory responses i.e., VCAM-1 and ICAM-1 
expression in response to TNFα through oxidative stress rather 
than  through  HBP  pathway,  since  inhibition  of  superoxide 
generation by resveratrol prevents the endothelial expression of the 
adhesion molecules stimulated by high glucose plus TNFα without 
inhibition of the global O-GlcNAc levels in the cells exposed to 
hyperglycemia, although alterations of O-GlcNAc modification of 
some proteins can not be fully excluded. Importantly, azaserine, 
a widely used GFAT inhibitor not only inhibits HBP pathway 
under  high  glucose  condition,  but  also  exerts  anti-oxidant  and 
anti-inflammatory effects in the endothelial cells under normo-
glycemic condition in response to TNFα, when no increase in 
HBP flux occurs.12 The results implicate that azaserine exhibits 
anti-oxidative  and  anti-inflammatory  effects  in  endothelial  cells 
independently of inhibition of HBP pathway. These pharmaco-
logical effects of azaserine should be taken into account, when 
the substance is used to analyze the role of the HBP pathway in a 
biological system.
In the current article, we presented further results showing that 
incubation of the endothelial cells with glucosamine to augment 
Figure 2. Effects of glucosamine on endothelial superoxide anion gen-
eration.  (A)  Dihydroethidium  (DHE)  fluorescence  staining  shows  that 
glucosamine itself (0.5 mmol/L, 5 days) induced superoxide generation 
in HUVECs and did not affect the effect of TNFα (1 ng/ml, 10 minutes, n 
= 3). (B) Quantification of the above results. *p < 0.05 and **p < 0.01 
vs. control.www.landesbioscience.com Oxidative Medicine and Cellular Longevity 175
Glucosamine, superoxide anion and ICAM-1 expression
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glucosamine  supplemented  with  a  lower  concentration  of  FCS 
(1%)  for  five  hours  followed  by  the  stimulation  with  TNFα   
(1 ng/ml) for additional 24 hours.
ICAM-1 and VCAM-1 protein expression. Cell lysate prepara-
tion, 8% SDS-PAGE and protein transfer from SDS-PAGE gels 
to  an  Immobilon-P  membrane  (Millipore)  were  performed  as 
described.12 The resultant membranes were first incubated with 
the individual primary antibody at room temperature for two to 
three hours after blocking with 5% skimmed milk. The blots were 
then incubated with a corresponding anti-mouse (Alexa fluor 680 
conjugated) or anti-rabbit (IRDye 800 conjugated) secondary anti-
body (1:5,000) for two hours, and the quantification of the signals 
was performed using the Odyssey Application Software 1.2.
DHE staining for superoxide anion generation. Superoxide 
anion  generation  was  analyzed  as  described.12  Images  were 
obtained with Zeiss fluorescence microscopy. The intensity of the 
fluorescence was quantified by Image J software.
Statistical analysis. All data were given as means ± SE. The 
ANOVA  with  Bonferroni  post  hoc  test  was  used  for  statistical 
analysis. A two-tailed value of p < 0.05 was considered to indicate 
a statistically significant difference.
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